An assessment of the future impact of alternative technologies on antibiotics markets

Journal of Pharmaceutical Policy and Practice

Volumn 9, Issue 1, 2016, Pages

  Nwokoro, Ejike ^a   Leach, Ross ^b   Årdal, Christine ^a   Baraldi, Enrico ^c   Ryan, Kellie ^d   Plahte, Jens ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UPPSALA UNIVERSITY   (Sweden)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; ANTIINFECTIVE AGENT; ANTIMICROBIAL NANOPARTICLE; BIOMATERIAL; POLYPEPTIDE ANTIBIOTIC AGENT; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VACCINE;

ALTERNATIVE MEDICINE; ARTICLE; BACTERIAL VIRULENCE; BACTERIOPHAGE; DRUG INDUSTRY; DRUG MARKETING; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; POINT OF CARE TESTING; TRANSPLANTATION;

EID: 84992316316     PISSN: None     EISSN: 20523211     Source Type: Journal    
DOI: 10.1186/s40545-016-0085-3     Document Type: Article

References (109)

1. Appelbaum PC. 2012 and beyond: potential for the start of a second pre-antibiotic era? Journal of Antimicrobial Chemotherapy. 2012;(67):2062-8
2. Declaration of the G7 Health Ministers, 8 - 9 October 2015 in Berlin [http://www.bmg.bund.de/fileadmin/dateien/Downloads/G/G7-Ges.Minister_2015/G7_Health_Ministers_Declaration_AMR_and_EBOLA.pdf]
3. European Parliament resolution of 19 May 2015 on safer healthcare in Europe: improving patient safety and fighting antimicrobial resistance (2014/2207(INI)) [http://www.europarl.europa.eu/sides/getDoc.do?pubRef=//EP//NONSGML+TA+P8-TA-2015-0197+0+DOC+PDF+V0//EN]
4. WHO. Global action plan on antimicrobial resistance. Geneva: World Health Organization; 2015.
5. At UN, global leaders commit to act on antimicrobial resistance [http://www.who.int/mediacentre/news/releases/2016/commitment-antimicrobial-resistance/en/]; 2016.
6. Dar OA, Hasan R, Schlundt J, Harbarth S, Caleo G, Dar FK, Littmann J, Rweyemamu M, Buckley EJ, Shahid M, et al. Exploring the evidence base for national and regional policy interventions to combat resistance. The Lancet. 2016;387(10015):285-95.
7. Das P, Horton R. Antibiotics: achieving the balance between access and excess. The Lancet. 2016;387(10014):102-4.
8. Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJV. Understanding the mechanisms and drivers of antimicrobial resistance. The Lancet. 2016;387(10014):176-87.
9. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, Davies S. Access to effective antimicrobials: a worldwide challenge. The Lancet. 2016;387(10014):168-75.
10. Mendelson M, Røttingen J-A, Gopinathan U, Hamer DH, Wertheim H, Basnyat B, Butler C, Tomson G, Balasegaram M. Maximising access to achieve appropriate human antimicrobial use in low-income and middleincome countries. The Lancet. 2016;387(10014):188-98.
11. Årdal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M, Ranganathan N, Smith R, Zorzet A, Cohn J, Pittet D, et al. International cooperation to improve access to and sustain effectiveness of antimicrobials. Lancet. 2016;387(10015):296-307.
12. Clift C, Gopinathan U, Morel C, Outterson K, Røttingen J-A, So AD. Towards a new global business model for antibiotics. Delinking revenues from sales. London: Chatham House - The Royal Institute of International Affairs; 2015.
13. Sertkaya A, Eyraud J, Birkenbach A, Franz C, Ackerley N, Overton V, Outterson K. Analytical framework for examining the value of antibacterial products. Washington DC: Eastern Research Group, Inc., report commissioned by the US Department of Health and Human Services; 2014.
14. Stephens P. Stimulating antibiotic R&D. An analysis of key factors - R&D success, R&D duration and the impact of generic launch. London: IMS Health; 2015.
15. Transatlantic Task Force on Antimicrobial Resistance (TATFAR) [http://www.cdc.gov/drugresistance/tatfar/]; 2016.
16. Review on Antimicrobial Resistance [http://amr-review.org/]; 2016.
17. Review AMR. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. London: Review on Antimicrobial Resistance; 2014.
18. Review AMR. Rapid diagnostics: Stopping unnecessary use of antibiotics. London: Review on Antimicrobial Resistance; 2015.
19. Review AMR. Securing new drugs for future generations: the pipeline of antibiotics. London: Review on Antimicrobial Resistance; 2015.
20. Review AMR. Antimicrobials in agriculture and the environment. Reducing unneccessary use and waste. London: Review on Antimicrobial Resistance; 2015.
21. Review AMR. Vaccines and alternative approaches: Reducing our dependence on antimicrobials. London: Review on Antimicrobial Resistance; 2016.
22. Review AMR. Tackling drug-resistant infections globally: Final report and recommendations. London: Review on Antimicrobial Resistance; 2016.
23. Driving reinvestment in research and development and responsible antibiotic use [http://drive-ab.eu/]; 2016.
24. Innovative Medicines Initiative [http://www.imi.europa.eu/]; 2016.
25. UAfEM. Tackling the antimicrobial resistance innovation crisis. Provisional Agenda Item 16.5 - Antimicrobial drug resistance, 67th World Health Assembly. Geneva: Universities Allied for Essential Medicines; 2014.
26. Allen HK, Trachsel J, Looft T, Casey TA. Finding alternatives to antibiotics. Ann N Y Acad Sci. 2014;1323(1):91-100.
27. Fernebro J. Fighting bacterial infections - future treatment options. Drug Resist Updat. 2011;14(2):125-39.
28. Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock REW, Harper D, et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis. 2016;16(2):239-51.
29. Mossialos E, Morel C, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D: Policies and incentives for promoting innovation in antibiotic research. In. London: European Observatory on Health Systems and Policies; 2010
30. Vaccines [http://www.who.int/topics/vaccines/en/]; 2015.
31. Hockenhull J, Dwan K, Smith G, Gamble C, Boland A, Walley T, Dickson R. The clinical effectiveness of central venous catheters treated with anti-infective agents in preventing catheter-related bloodstream infections: a systematic review. Crit Care Med. 2009;37(2):702-12.
32. Probiotics [http://www.nhs.uk/Conditions/probiotics/Pages/Introduction.aspx]; 2014.
33. Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerging infectious diseases. 2010;16(11):1661-5.
34. Hempel S, Newberry SJ, Maher AR, Wang Z, Miles JN, Shanman R, Johnsen B, Shekelle PG. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959-69.
35. An improved standard of care for the treatment of ear infections [http://www.entratympanic.com/]; 2015.
36. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature J. 2002;415(6870):389-95.
37. Hajipour M, Fromm K, Ashkarran A, Jimenez de Aberasturi D, de Larramendi I, Rojo T, Serpooshan V, Parak W, Mahmoudi M. Antibacterial properties of nanoparticles. Trends Biotechnol. 2012;30(10):499-511.
38. Longitude Prize [https://longitudeprize.org/view-entries]; 2015.
39. Reichert J, Rosensweig C, Faden L, Dewitz M. Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005;23(9):1073-8.
40. CDC. Antibiotic resistance threats in the United States, 2013. Atlanta: Centers for Disease Control and Prevention; 2013.
41. PhRMA. Medicines in development - vaccines. A report on teh prevention and treatment of disease through vaccines. Washington DC: Pharmaceutical Research and Manufacturers of America; 2013.
42. Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis. 2008;8(12):785-95.
43. Song J-H, Dagan R, Klugman KP, Fritzell B. The relationship between pneumococcal serotypes and antibiotic resistance. Pediatr Pol. 2013;88(6):T25-37.
44. van de Vooren K, Duranti S, Curto A, Garattini L. Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics. 2014;32(1):29-45.
45. PATH & bvgh. The case for investment in enterotoxigenic Escherichia coli vaccines. PATH and Bio Ventures for Global Health: Seattle & San Fransisco; 2011.
46. DoCAL. Multi-criteria analysis: a manual. London: Department of Community and Local Government; 2009.
47. Kitzinger J. The methodology of Focus Groups: the importance of interaction between research participants. Sociol Health Illn. 1994;16(7):103-21.
48. Hoffman RR, Shadbolt NR, Burton MA, Klein G. Eliciting knowledge from experts: A methodological analysis. Organ Behav Hum Decis Process. 1995;62(2):129-58.
49. Banoo S, Bell D, Bossuyt P, Herring A, Mabey D, Poole F, Smith PG, Sriram N, Wongsrichanalai C, Linke R. Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol. 2008;8:S16-28.
50. Caliendo AM, Gilbert DN, Ginocchio CC, Hanson KE, May L, Quinn TC, Tenover FC, Alland D, Blaschke AJ, Bonomo RA, et al. Better tests, better care: Improved diagnostics for infectious diseases. Clin Infect Dis. 2013;57 suppl 3:S139-70.
51. Finch R, Hunter PA. Antibiotic resistance-action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005. J Antimicrob Chemother. 2006;58 suppl 1:i3-i22.
52. Holland CA, Kiechle FL. Point-of-care molecular diagnostic systems-past, present and future. Curr Opin Microbiol. 2005;8(5):504-9.
53. Okeke IN, Peeling RW, Goossens H, Auckenthaler R, Olmsted SS, de Lavison J-F, Zimmer BL, Perkins MD, Nordqvist K. Diagnostics as essential tools for containing antibacterial resistance. Drug Resist Updat. 2011;14(2):95-106.
54. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, Dhar A, Brown H, Foden A, Gravenor MB. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;382(9900):1249-57.
55. Beerepoot AJ, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM, Prins JM, Koeijers J, Verbon A, Stobberingh E, et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. Arch Intern Med. 2012;172(9):704-12.
56. Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C difficile infection: A randomized clinical trial. JAMA. 2015;313(17):1719-27.
57. Hojsak I, Abdović S, Szajewska H, Milošević M, Krznarić Ž, Kolaček S. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics. 2010;125(5):e1171-7.
58. Klarin B, Molin G, Jeppsson B, Larsson A. Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care. 2008;12(6):R136.
59. Manzoni P, Mostert M, Leonessa M, Priolo C, Farina D, Monetti C, Latino M, Gomirato G. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis. 2006;42(12):1735-42.
60. Pozzoni P, Riva A, Bellatorre AG, Amigoni M, Redaelli E, Ronchetti A, Stefani M, Tironi R, Molteni EE, Conte D. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2012;107(6):922-31.
61. Jones R, Jacobs M, Sader H. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents. 2010;36(3):197-204.
62. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53(10):994-1002.
63. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal Microbiota transplantation for clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500-8.
64. Kelly CP. Fecal microbiota transplantation - an old therapy comes of age. N Engl J Med. 2013;368(5):474-5.
65. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407-15.
66. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312(17):1772-8.
67. Casadevall A. Antibody-based therapies for emerging infectious diseases. Emerg Infect Dis. 1996;2(3):200.
68. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Science Translational Med. 2014;6(262 262ra155):1-12.
69. Kummerfeldt CE. Raxibacumab: potential role in the treatment of inhalational anthrax. Infection Drug Resistance. 2014;7:101-9.
70. Ly-Chatain MH: The factors affecting effectiveness of treatment in phages therapy. Frontiers in Microbiology 2014, 5(18 February).
71. Reardon S. Phage therapy gets revitalized. Nature. 2014;510(5):15-6.
72. Baltzer SA, Brown MH. Antimicrobial peptides - promising alternatives to conventional antibiotics. J Mol Microbiol Biotechnol. 2011;20(4):228-35.
73. Bell G, Gouyon P-H. Arming the enemy: the evolution of resistance to self-proteins. Microbiology. 2003;149(6):1367-75.
74. Guaní-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Terán LM. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol. 2010;135(1):1-11.
75. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30(3):131-41.
76. Marr AK, Gooderham WJ, Hancock RE. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol. 2006;6(5):468-72.
77. Gao P, Nie X, Zou M, Shi Y, Cheng G. Recent advances in materials for extended-release antibiotic delivery system. J Antibiot. 2011;64(9):625-34.
78. Lara Y, Nguyen T, Marilena L, Alexander M. Toxicological considerations of clinically applicable nanoparticles. Nano Today. 2011;6:585-607.
79. Markowska K, Grudniak AM, Wolska KI. Silver nanoparticles as an alternative strategy against bacterial biofilms. Acta Biochim Pol. 2013;60(4):523-30.
80. Ranghar S, Sirohi P, Verma P, Agarwal V. Nanoparticle-based drug delivery systems: promising approaches against infections. Braz Arch Biol Technol. 2014;57(2):209-22.
81. Singh K, Panghal M, Kadyan S, Chaudhary U, Yadav JP. Antibacterial activity of synthesized silver nanoparticles from Tinospora cordifolia against multi drug resistant strains of Pseudomonas aeruginosa isolated from burn patients. J Nanomed Nanotechnol. 2014;5(2).
82. Sundar S, Prajapati VK. Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules. Curr Med Chem. 2012;19(19):3196.
83. Taylor E, Webster TJ. Reducing infections through nanotechnology and nanoparticles. Int J Nanomedicine. 2011;6:1463.
84. Bayston R, Ashraf W, Bhundia C. Mode of action of an antimicrobial biomaterial for use in hydrocephalus shunts. J Antimicrob Chemother. 2004;53(5):778-82.
85. Campoccia D, Montanaro L, Speziale P, Arciola CR. Antibiotic-loaded biomaterials and the risks for the spread of antibiotic resistance following their prophylactic and therapeutic clinical use. Biomaterials. 2010;31(25):6363-77.
86. Elsner JJ, Berdicevsky I, Zilberman M. In vitro microbial inhibition and cellular response to novel biodegradable composite wound dressings with controlled release of antibiotics. Acta Biomater. 2011;7(1):325-36.
87. Hendriks J, Van Horn J, Van Der Mei H, Busscher H. Backgrounds of antibiotic-loaded bone cement and prosthesis-related infection. Biomaterials. 2004;25(3):545-56.
88. Shukla A, Fleming KE, Chuang HF, Chau TM, Loose CR, Stephanopoulos GN, Hammond PT. Controlling the release of peptide antimicrobial agents from surfaces. Biomaterials. 2010;31(8):2348-57.
89. Alksne LE, Projan SJ. Bacterial virulence as a target for antimicrobial chemotherapy. Curr Opin Biotechnol. 2000;11(6):625-36.
90. Baron C. Antivirulence drugs to target bacterial secretion systems. Curr Opin Microbiol. 2010;13(1):100-5.
91. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol. 2008;6(1):17-27.
92. Escaich S. Antivirulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol. 2008;12(4):400-8.
93. Melstrom Jr KA, Smith JW, Gamelli RL, Shankar R. New perspectives for a new century: implications of pathogen responses for the future of antimicrobial therapy. J Burn Care Res. 2006;27(3):251-64.
94. Hauser AR, Mecsas J, Moir DT. Beyond antibiotics: New therapeutic approaches for bacterial infections. Clin Infect Dis. 2016;63(1):89-95.
95. Rex JH, Goldberger M, Eisenstein BI, Harney C. The evolution of the regulatory framework for antibacterial agents. Ann N Y Acad Sci. 2014;1323(1):11-21.
96. Baraldi E, Gregori G, Perna A. Network evolution and the embedding of complex technical solutions: The case of the Leaf House network. Ind Mark Manag. 2011;40:838-52.
97. Håkansson H, Waluszewski A, editors. Knowledge and innovation in business and industry. The importance of using others. London: Routledge; 2007.
98. Grimshaw J, Thomas R, MacLennan G, Fraser C, Ramsay C, Vale L, Whitty P. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004;8(6):1-72.
99. Adang E, Wensing M. Economic barriers to implementation of innovations in health care: is the long run-short run efficiency discrepancy a paradox? Health Policy. 2008;88(2-3):236-42.
100. Wagrell S, Waluszewski A. The innovation process and its organisational setting - fit or misfit? IMP J. 2009;3(2):57-85.
101. Berben SA, Meijs T, van Grunsven P, Schoonhoven L, van Achterberg T. Facilitators and barriers in pain management for trauma patients in the chain of emergency care. Injury. 2011;43(9):1397-402.
102. Elston M. The politics of professional power: medicine in a changing health service. The sociology of the health service. London: Routledge; 1991.
103. Bartos CE. Perceptions of personal power and their relationship to clinician's resistance to the introduction of computerized physician order entry. Pittsburgh: University of Pittsburgh; 2008.
104. Garman A, Leach D. Worldviews in collision: conflict and collaboration across professional lines. J Organ Behav. 2006;27:829-49.
105. Farmer A, Legare F, Turcot L, Grimshaw J, Harvey E, McGowan JL, Wolf F: Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database System Review 2008, 16(3).
106. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in Medicine: Therapeutic Applications and Developments. Clin Pharmacol Ther. 2008;83(5):761-9.
107. Ruer S, Pinotsis N, Steadman D, Waksman G, Remaut H. Virulence-targeted antibacterials: concept, promise, and susceptibility to resistance mechanisms. Chem Biol Drug Des. 2015;86(4):379-99.
108. Goldin B, Gorbach S. Clinical indications for probiotics: an overview. Clin Infect Dis. 2008;46(2):S96-S100.
109. Bebbington C, Yarranton G. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol. 2008;19(6):613-9.